Merck & Co.

AWARDS

NEWS

BioCapital

Clinical Catch-Up: March 30 – April 3

This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.

April 3, 2020

·

14 min read

·

Drug Development

Biopharma Update on the Novel Coronavirus: April 2

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.

April 2, 2020

·

7 min read

·

BioSpace Editorial Staff

Drug Development

Merck’s Keytruda Hits Coprimary Endpoint Early in Colorectal Cancer Trial

Keytruda (pembrolizumab) hit one of the coprimary endpoints early in the Phase III KEYNOTE-177 clinical trial for a highly mutating form of colorectal cancer.

April 2, 2020

·

2 min read

·

Drug Development

BMS, Merck and Pfizer Join List of Companies Pausing Some Clinical Trials During Pandemic

As COVID-19 continues to expand across the globe, more pharmaceutical companies are hitting the brakes on clinical trials as part of an effort to ease the burden on doctors and facilities needed to treat patients combating the disease.

March 27, 2020

·

3 min read

·

Drug Development

Biopharma Industry News for March 27: Update on the Novel Coronavirus

A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.

March 27, 2020

·

3 min read

·

BioSpace Editorial Staff

Drug Development

Biopharma Industry News for March 26: Update on the Novel Coronavirus

A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.

March 26, 2020

·

5 min read

·

BioSpace Editorial Staff

JOBS

IN THE PRESS

Press Releases

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

March 2, 2026

·

19 min read

Press Releases

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

March 2, 2026

·

19 min read

Press Releases

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

March 2, 2026

·

19 min read

Press Releases

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

March 2, 2026

·

19 min read

Press Releases

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

February 26, 2026

·

2 min read

Press Releases

FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis

February 26, 2026

·

8 min read

Press Releases

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

February 26, 2026

·

19 min read

Press Releases

Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge

February 24, 2026

·

8 min read

Press Releases

Merck to Participate in the TD Cowen 46th Annual Health Care Conference

February 24, 2026

·

3 min read

Press Releases

Merck Evolves Human Health Operating Structure to Support Portfolio Execution

February 23, 2026

·

5 min read